DANVERS, Mass.--(BUSINESS WIRE)--BioChemics, Inc. (BCI), a company “enhancing drug delivery through biophysical modulation,” is pleased to announce the signing of a research collaboration agreement with Cynosure, Inc. (NASDAQ:CYNO), a leading developer and manufacturer of light-based aesthetic treatment systems, to evaluate the use of BCI's VALE® based compositions in conjunction with light based aesthetic treatments. BioChemics is a specialty pharmaceutical company that has developed a novel, transdermal drug delivery system called VALE® (Vaso-active Lipid Encapsulated), that allows a wide variety of actives to be delivered into the skin.
